Inactive Instrument
Taro Pharmaceutical Industries Ltd. Share Price Other OTC
Stocks
IL0010827181
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 06-30 | FDA Grants Tentative Approval for ANDA 212581 Azelaic Acid Topical Foam | CI |
| 24/06/24 | Taro Pharmaceutical Industries Ltd.(NYSE:TARO) dropped from S&P Global BMI Index | CI |
| Manager | Title | Age | Since |
|---|---|---|---|
William Coote
DFI | Director of Finance/CFO | 71 | 30/11/2021 |
Richard Glaze
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Hagai Reingold
COO | Chief Operating Officer | - | 31/12/2001 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 31/08/2010 | |
James Kedrowski
BRD | Director/Board Member | 74 | 17/05/2011 |
| Chairman | 70 | 22/09/2010 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.03% | -4.60% | +54.17% | +151.01% | 1,030B | |
| +0.81% | -2.26% | +56.27% | +53.67% | 617B | |
| -1.18% | -2.23% | +34.15% | +69.52% | 455B | |
| +0.24% | -0.14% | +37.92% | +31.04% | 350B | |
| -0.11% | -0.22% | +34.43% | +39.04% | 299B | |
| -0.42% | +0.03% | +11.92% | +13.30% | 265B | |
| -7.37% | -4.40% | -2.54% | -43.87% | 225B | |
| -1.19% | +1.75% | +29.65% | +63.40% | 209B | |
| -0.91% | +0.78% | +16.05% | +71.15% | 163B | |
| Average | -1.26% | +4.83% | +30.23% | +49.81% | 401.41B | |
| Weighted average by Cap. | -0.92% | +4.87% | +39.02% | +72.32% |
Employees
-
Sector
Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
